Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Harvard Business School
Express Scripts
AstraZeneca
Medtronic

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR BESIVANCE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Besivance

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00347932 ↗ A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. Completed Bausch & Lomb Incorporated Phase 3 2006-06-01 Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.
NCT00824070 ↗ Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects Completed Bausch & Lomb Incorporated Phase 1 2009-02-01 This study is being conducted to assess the concentration of besifloxacin, moxifloxacin, or gatifloxacin in aqueous humor samples collected following topical instillation of the associated formulation in subjects undergoing cataract surgery.
NCT00905762 ↗ Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation Completed Bausch & Lomb Incorporated Phase 1 2009-03-01 The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days.
NCT00924729 ↗ Study of Ocular Penetration of Topically Administered Fluoroquinolones Completed Johns Hopkins University Phase 4 2009-09-01 This study is being conducted to evaluate the intraocular penetration of Moxifloxacin 0.5% ophthalmic solution (Vigamox) and Besifloxacin 0.6% ophthalmic suspension (Besivance) after pre-operative topical administration in subjects undergoing cataract surgery.
NCT00972777 ↗ Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Completed Bausch & Lomb Incorporated Phase 2/Phase 3 2009-10-01 This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
NCT01175590 ↗ Safety of Besivanceā„¢ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Completed Bausch & Lomb Incorporated Phase 3 2010-06-01 The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Besivance

Condition Name

Condition Name for Besivance
Intervention Trials
Bacterial Conjunctivitis 4
Cataract Extraction 2
Corneal Health 1
Dry Eye Syndromes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Besivance
Intervention Trials
Conjunctivitis, Bacterial 5
Conjunctivitis 5
Cataract 4
Keratoconjunctivitis Sicca 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Besivance

Trials by Country

Trials by Country for Besivance
Location Trials
United States 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Besivance
Location Trials
New York 6
New Jersey 2
Kentucky 1
Missouri 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Besivance

Clinical Trial Phase

Clinical Trial Phase for Besivance
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Besivance
Clinical Trial Phase Trials
Completed 10
Terminated 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Besivance

Sponsor Name

Sponsor Name for Besivance
Sponsor Trials
Bausch & Lomb Incorporated 10
John, George, M.D. 1
Ocular Therapeutix, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Besivance
Sponsor Trials
Industry 12
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Moodys
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.